Aspen and a subsidiary of global brand Johnson & Johnson, Janssen Pharmaceuticals, have signed a provisional agreement that will see Aspen Pharmacare manufacturing J&J’s Covid-19 vaccine candidate at its plant in Port Elizabeth., is currently in stage 3 of clinical trials and is one of the leading trials underway at present, with 60,000 adults in eight countries including South Africa and the US.
Whether or not the trial is a success, the agreement with Aspen is still subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.“We have to see whether this vaccine succeeds and whether it can get traction in global delivery. What is important for us, is that we have been recognised as a company that can operate in this space.
It has invested in a high containment facility in Port Elizabeth which allows it to produce state-of-the-art sterile drugs and vaccines, packaged into vials, ampoules and pre-filled syringes.
Is the NorthWestDOH contributing in any way or form, DlaminiZuma DrZweliMkhize MokgoroJob